Flow-metabolism uncoupling in the cervical spinal cord of ALS patients

Toru Yamashita, Tetsuhiro Hatakeyama, Kota Sato, Yusuke Fukui, Nozomi Hishikawa, Yasuyuki Ohta, Yoshihiro Nishiyama, Nobuyuki Kawai, Takashi Tamiya, Koji Abe

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease. In ALS, both glucose consumption and neuronal intensity reportedly decrease in the cerebral motor cortex when measured by positron emission tomography (PET). In this study, we evaluated cervical spinal glucose metabolism, blood flow, and neuronal intensity of 10 ALS patients with upper extremity (U/E) atrophy both with 18F-2-fluoro-2-deoxy-d-glucose (18F-FDG) PET and 11C-flumazenil (11C-FMZ) PET. On the ipsilateral side of C5 and T1 levels, 18F-FDG uptake increased significantly (*p < 0.05), and was correlated with the rate of progression of the ALS FRS-R-U/E score (R = 0.645, *p = 0.041). Despite this hyperglucose metabolism, the 11C-FMZ PET study did not show a coupled increase of spinal blood flow even though neuronal intensity did not decrease. These results indicate a strong correlation between hyperglucose metabolism and ALS progression alongside the uncoupling of flow-metabolism. This mechanism, which could result in subsequent motor neuronal death, may be a potential therapeutic target for ALS.

Original languageEnglish
Pages (from-to)659-665
Number of pages7
JournalNeurological Sciences
Volume38
Issue number4
DOIs
Publication statusPublished - Apr 1 2017

Fingerprint

Amyotrophic Lateral Sclerosis
Positron-Emission Tomography
Flumazenil
Glucose
Upper Extremity
Motor Neuron Disease
Motor Cortex
Cerebral Cortex
Atrophy
Blood Glucose
Cervical Cord

Keywords

  • C-FMZ
  • F-FDG
  • ALS
  • Flow-metabolism uncoupling
  • Glucose metabolism
  • PET

ASJC Scopus subject areas

  • Dermatology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Flow-metabolism uncoupling in the cervical spinal cord of ALS patients. / Yamashita, Toru; Hatakeyama, Tetsuhiro; Sato, Kota; Fukui, Yusuke; Hishikawa, Nozomi; Ohta, Yasuyuki; Nishiyama, Yoshihiro; Kawai, Nobuyuki; Tamiya, Takashi; Abe, Koji.

In: Neurological Sciences, Vol. 38, No. 4, 01.04.2017, p. 659-665.

Research output: Contribution to journalArticle

Yamashita, Toru ; Hatakeyama, Tetsuhiro ; Sato, Kota ; Fukui, Yusuke ; Hishikawa, Nozomi ; Ohta, Yasuyuki ; Nishiyama, Yoshihiro ; Kawai, Nobuyuki ; Tamiya, Takashi ; Abe, Koji. / Flow-metabolism uncoupling in the cervical spinal cord of ALS patients. In: Neurological Sciences. 2017 ; Vol. 38, No. 4. pp. 659-665.
@article{e8b34d91a3b849ec9a2435bea30289e8,
title = "Flow-metabolism uncoupling in the cervical spinal cord of ALS patients",
abstract = "Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease. In ALS, both glucose consumption and neuronal intensity reportedly decrease in the cerebral motor cortex when measured by positron emission tomography (PET). In this study, we evaluated cervical spinal glucose metabolism, blood flow, and neuronal intensity of 10 ALS patients with upper extremity (U/E) atrophy both with 18F-2-fluoro-2-deoxy-d-glucose (18F-FDG) PET and 11C-flumazenil (11C-FMZ) PET. On the ipsilateral side of C5 and T1 levels, 18F-FDG uptake increased significantly (*p < 0.05), and was correlated with the rate of progression of the ALS FRS-R-U/E score (R = 0.645, *p = 0.041). Despite this hyperglucose metabolism, the 11C-FMZ PET study did not show a coupled increase of spinal blood flow even though neuronal intensity did not decrease. These results indicate a strong correlation between hyperglucose metabolism and ALS progression alongside the uncoupling of flow-metabolism. This mechanism, which could result in subsequent motor neuronal death, may be a potential therapeutic target for ALS.",
keywords = "C-FMZ, F-FDG, ALS, Flow-metabolism uncoupling, Glucose metabolism, PET",
author = "Toru Yamashita and Tetsuhiro Hatakeyama and Kota Sato and Yusuke Fukui and Nozomi Hishikawa and Yasuyuki Ohta and Yoshihiro Nishiyama and Nobuyuki Kawai and Takashi Tamiya and Koji Abe",
year = "2017",
month = "4",
day = "1",
doi = "10.1007/s10072-017-2823-y",
language = "English",
volume = "38",
pages = "659--665",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia",
number = "4",

}

TY - JOUR

T1 - Flow-metabolism uncoupling in the cervical spinal cord of ALS patients

AU - Yamashita, Toru

AU - Hatakeyama, Tetsuhiro

AU - Sato, Kota

AU - Fukui, Yusuke

AU - Hishikawa, Nozomi

AU - Ohta, Yasuyuki

AU - Nishiyama, Yoshihiro

AU - Kawai, Nobuyuki

AU - Tamiya, Takashi

AU - Abe, Koji

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease. In ALS, both glucose consumption and neuronal intensity reportedly decrease in the cerebral motor cortex when measured by positron emission tomography (PET). In this study, we evaluated cervical spinal glucose metabolism, blood flow, and neuronal intensity of 10 ALS patients with upper extremity (U/E) atrophy both with 18F-2-fluoro-2-deoxy-d-glucose (18F-FDG) PET and 11C-flumazenil (11C-FMZ) PET. On the ipsilateral side of C5 and T1 levels, 18F-FDG uptake increased significantly (*p < 0.05), and was correlated with the rate of progression of the ALS FRS-R-U/E score (R = 0.645, *p = 0.041). Despite this hyperglucose metabolism, the 11C-FMZ PET study did not show a coupled increase of spinal blood flow even though neuronal intensity did not decrease. These results indicate a strong correlation between hyperglucose metabolism and ALS progression alongside the uncoupling of flow-metabolism. This mechanism, which could result in subsequent motor neuronal death, may be a potential therapeutic target for ALS.

AB - Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease. In ALS, both glucose consumption and neuronal intensity reportedly decrease in the cerebral motor cortex when measured by positron emission tomography (PET). In this study, we evaluated cervical spinal glucose metabolism, blood flow, and neuronal intensity of 10 ALS patients with upper extremity (U/E) atrophy both with 18F-2-fluoro-2-deoxy-d-glucose (18F-FDG) PET and 11C-flumazenil (11C-FMZ) PET. On the ipsilateral side of C5 and T1 levels, 18F-FDG uptake increased significantly (*p < 0.05), and was correlated with the rate of progression of the ALS FRS-R-U/E score (R = 0.645, *p = 0.041). Despite this hyperglucose metabolism, the 11C-FMZ PET study did not show a coupled increase of spinal blood flow even though neuronal intensity did not decrease. These results indicate a strong correlation between hyperglucose metabolism and ALS progression alongside the uncoupling of flow-metabolism. This mechanism, which could result in subsequent motor neuronal death, may be a potential therapeutic target for ALS.

KW - C-FMZ

KW - F-FDG

KW - ALS

KW - Flow-metabolism uncoupling

KW - Glucose metabolism

KW - PET

UR - http://www.scopus.com/inward/record.url?scp=85010735796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010735796&partnerID=8YFLogxK

U2 - 10.1007/s10072-017-2823-y

DO - 10.1007/s10072-017-2823-y

M3 - Article

VL - 38

SP - 659

EP - 665

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 4

ER -